Metabolomics in Chronic Kidney Diseases: Here to Stay
1 Department of Internal Medicine II—Nephrology, Victor Babeș University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041 Timișoara, Romania; (M.-R.P.); (F.G.); (L.B.); (S.I.)
2 Centre for Molecular Research in Nephrology and Vascular Disease, Victor Babeș University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041 Timișoara, Romania; (A.V.); (D.C.J.); (C.S.)
3 Center for Translational Research and Systems Medicine, Victor Babeș University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041 Timișoara, Romania;
4 Department of Internal Medicine II—Diabetes and Metabolic Diseases, Victor Babeș University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041 Timișoara, Romania
5 Department of Functional Sciences—Pathophysiology, Victor Babeș University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041 Timișoara, Romania
6 Department of Neurosciences—Neurology, Victor Babeș University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041 Timișoara, Romania
7 Centre for Cognitive Research in Neuropsychiatric Pathology, Victor Babeș University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041 Timișoara, Romania
8 Department of Food Science, Faculty of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine Cluj-Napoca, 400372 Cluj-Napoca, Romania
* Correspondence: (L.P.); (D.M.M.)
* Author to whom correspondence should be addressed.
Received: 10 Dec 2020 / Accepted: 4 Feb 2021 / Published: 16 Feb 2021
Abstract
Chronic kidney disease (CKD) affects around 13% of the adult population, has become a considerable concern worldwide, and is characterized by inadequate renal clearance, resulting in the accumulation of various potential toxic compounds. Metabolomics, one of the many important parts of “omics” science, refers to the systematic study of metabolites in a living system and their changes because of pathophysiological and genetic modifications. The use of metabolomics in the nephrology field of research has offered a better understanding of the pathomechanisms of CKD. The most recent technologies used for the evaluation of plasma and urinary metabolites are nuclear magnetic resonance (NMR) and mass spectroscopy (MS). A major research direction of modern medicine is to develop new therapies and new biomarkers for the early diagnosis of patients with CKD. Experimental studies of renal metabolism unequivocally demonstrated that kidney function has a huge impact on several circulating metabolites. Moreover, metabolites themselves appear to have an essential role in CKD pathogenesis/complications, being recognized as potential biomarkers with prognostic, diagnostic, and therapeutic value for the disease. The present paper provides a bird’s eye view on metabolomics and a summary of the most recent studies of metabolomics carried out in patients with CKD.
Keywords: metabolomics; biomarkers; chronic kidney disease
OPEN ACCESS
This is an open access article distributed under the Creative Commons Attribution
License which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited. (CC BY 4.0).
CITE
Pătruică, M.-R.; Gădălean, F.; Vlad, A.; Sturza, A.; Jianu, D.C.; Balint, L.; Ienciu, S.; Petrica, L.; Muntean, D.M.; Socaciu, C. Metabolomics in Chronic Kidney Diseases: Here to Stay. Timisoara_Med 2021, 2020, 8.
Pătruică M-R, Gădălean F, Vlad A, Sturza A, Jianu DC, Balint L, Ienciu S, Petrica L, Muntean DM, Socaciu C. Metabolomics in Chronic Kidney Diseases: Here to Stay. Timisoara Medical Journal. 2021; 2020(2):8.
Pătruică, Mihaela-Roxana; Gădălean, Florica; Vlad, Adrian; Sturza, Adrian; Jianu, Dragos Cătălin; Balint, Lavinia; Ienciu, Silvia; Petrica, Ligia; Muntean, Danina M.; Socaciu, Carmen. 2021. "Metabolomics in Chronic Kidney Diseases: Here to Stay." Timisoara_Med 2020, no. 2: 8.
Not implemented
SHARE
